 Connection
David Magid to Cost-Benefit Analysis
This is a "connection" page, showing publications David Magid has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.232 |
|
|
|
-
Billups SJ, Moore LR, Olson KL, Magid DJ. Cost-effectiveness evaluation of a home blood pressure monitoring program. Am J Manag Care. 2014 Sep 01; 20(9):e380-7.
Score: 0.091
-
Magid D, Hill SA. Stress testing: it is safe to wait. Ann Emerg Med. 2006 May; 47(5):436-7.
Score: 0.051
-
Magid D, Douglas JM, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med. 1996 Feb 15; 124(4):389-99.
Score: 0.025
-
Magid D, Schwartz BS, Craft J, Schwartz JS. Antimicrobial prophylaxis after tick bites. N Engl J Med. 1993 May 13; 328(19):1419; author reply 1420.
Score: 0.021
-
Magid D, Schwartz B, Craft J, Schwartz JS. Prevention of Lyme disease after tick bites. A cost-effectiveness analysis. N Engl J Med. 1992 Aug 20; 327(8):534-41.
Score: 0.020
-
Smith DH, Feldstein AC, Perrin NA, Yang X, Rix MM, Raebel MA, Magid DJ, Simon SR, Soumerai SB. Improving laboratory monitoring of medications: an economic analysis alongside a clinical trial. Am J Manag Care. 2009 May; 15(5):281-9.
Score: 0.016
-
Panepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr. 2000 Feb; 136(2):201-8.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|